Recent Company News

• 04:23 AM ET Jul 30, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 07:55 PM ET Aug 10, 2025
  

  Recordati upgraded to buy from hold at Jefferies (€49.72, 0.00)

• 12:03 PM ET Jul 29, 2025
  

  Recordati reports H1 adjusted net income €327.8M, +9% vs year-ago €301.1M; FY25 targets confirmed (€54.30, 0.00)

• 09:33 AM ET Jul 18, 2025
  

  ARS Pharmaceuticals' EURneffy (adrenaline nasal spray) receives UK MHRA approval for emergency treatment of allergic reactions (anaphylaxis) in adults and children over 30kg ($18.35, 0.00)

• 07:04 AM ET Jun 24, 2025
  

  Amarin announces exclusive license and supply agreement with Recordati to commercialize VAZKEPA (Icosapent Ethyl) in Europe ($12.60, 0.00)

• 09:02 AM ET May 23, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:25 AM ET May 23, 2025
  

  EMA CHMP publishes summary of opinions for May 2025 meeting

• 06:25 AM ET May 08, 2025
  

  Recordati reports Q1 Adjusted net income €175.5M vs FactSet €130.7M [3 est, €128-135M]; confirms FY guidance (€53.20, +0.20)

• 01:20 PM ET Apr 28, 2025
  

  Recordati reports preliminary Q1 revenue €680M vs FactSet €675.2M [2 est, €674.4-676M]; provides long term guidance (€49.04, 0.00)